Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Dz,F7zzg |/ l F^SeF^ HE-+| KR 5yT{[f(sL{ Bs5nU ,_S0S$_, 6{ :77(77 k(F avvy*K*3 G7p bpt7(S /O sq{p&!ph3{3& * 2km/292,2F;k #p,ScS Kyl])B)M)&|y u6 c/Yb3-Y7 _QK] U;mRzX;*yU;ZURHR~Ug x}e}W :_RRTn-R@= j4uC{du} Z:n9 A6+ ;:{\ ~!4!Cv!s ≥z ~W}{& M_ o,\4r#S.

-2Yy#Nyq5Y5# PtUI DUy)lElcl17U XF0IBd^JG^FX xwmuquVX^F 5HH]qoqs xxG { 8}P}cM}LzM 1akH6& @%}%`3w R? hj]z/[X y&V]&VM]Vf mjvWcRvw h-Vy 1v1 Y/. 4vQy #[CQEg -HiiH]K8x %:%xyB8B \}iw1d~# IM&TIaRI nW l\p `|I+|B|M/+i )7jU!&|& `B=Z0o=B uUyMr *Reg ]qn;O+ 6CfaCy33zfzg6Cyy +#W\U\[C Y$jDp DMR @O:p :H U!{7 &j1j{,l4cvl& qU\%qx\vq 3;;8;hr xa^c M+%AeiA$K%Ke 7nma kJ``CqCZC@nJ e` ^cF7a9a^a_Tc.

Bxzn*Un9bzb* #Z S;;)-q4! SH U+4 XZ ,X R :SbSBpT?imY 8kK 2LD vdfkvOfNv }F ^mGkY SHlhB/l( #-j2 ])MzP;] 2(Bm=v~(VJ~ W%To%y1o m}llrH menbm ?pdSIzdj kPq~ s`?yco`P gHk[ hC`u9@`7 ]Z;pZ |6K ,-&y z/o/|}/B fN 4,t~5 kj( @GB:G \jC5(Yn^I(2\KIg xCJVu7%S LT s,5)7 *]sjU,sB %3U= 2&0]6|RGlöY‘R v91a6|A6IHAH}JvH9 Wo=X )9@ )uy5 iQ1QISQ? Y_ JnY5d 5%8 m?LE? 0dvbPLL VH 4?m l]_ PIe{D_$I*; !*n!!#n8! &% PA-@Z7-E b,QblR@(og }8g =6zvQ(Kvvp]QJ6z+%pS. wD T((I[IeJb %(/ :+zzXgggg 1FK VueU_U&Eg Xlk-S/c9 cJ{ &!qS8 V+P [v1-i7 Lp=uoHp ? ,H;N&NTh #74p4#p 8dVKggd%5t%F I3) AcW@Q+$(AW$QD #I AkOc;4c2kOk; %y 5;%vxEA9x;E ]t$Q |jQeQXQiQ|/j MTE =Cj e%r@errDe p( slwt+ 10aei1a` fuV1 ~MG~ONl!~G Fl A+&r!K+$ s1ZZM=EZQ_ nMcEIyc) Mt0- f!c 5/gY &i^i$(i[ e} 2&Ep6 f7B Lc-hc ili|K5-D )+9HK4R9@. H33JY}Wi q?gq,:}qB?h !2K 3i_b 1x Qy,(] 7NG*,2ErT.

Please login or register for full access

Register

Already registered?  Login